All News

Living Well With Metastatic Breast Cancer

December 13th 2008

CURE publisher Susan McClure blogs from a survivor's perspective.

Questions Emerge On Proper Use of Diagnostic Tools

December 13th 2008

CURE Editor-in-Chief Debu Tripathy, MD, blogs on medical issues from SABCS.

A Winning Combination

December 13th 2008

A combination of two well known breast cancer drugs could prove very successful when treating hormone receptor-positive, HER2-positive metastatic disease.

Full-Time Advocate: Bringing SABCS cutting-edge information back home

December 13th 2008

A look at how two-time breast cancer survivor Joan Venticinque got her start in advocacy and where she thinks the future may take her.

Data Confirms Zometa Reduces Bone Loss and Recurrence Risk

December 13th 2008

A brief discussing findings from this year's San Antonio Breast Cancer Symposium showing that research suggests that the drug Zometa may provide patients with reduced bone loss and a lesser chance of recurrence.

Phase III Trial Planned for RAD001 with Herceptin-Chemo Combo

December 13th 2008

A brief discussing investigation agent RAD001 (everolimus), a drug currently approved to treat kidney cancer, and the findings that now show the drug may be used to treat breast cancer.

Herceptin Before Surgery Highly Effective in Locally Advanced Breast Cancer

December 13th 2008

A brief discussing the data from the NOAH trial in which Herceptin was added to chemotherapy before surgery for HER2-positive locally advanced breast cancer.

Male Breast Cancer: Not Pink and Not Enough Awareness

December 13th 2008

Looking for Answers to Recurrence Years After Surgery

December 13th 2008

CURE Editor-in-Chief Debu Tripathy, MD, blogs on medical issues from SABCS.

Being Your Own Advocate

December 12th 2008

CURE publisher Susan McClure blogs from a survivor's perspective.

Komen Awards Give Recognition to Leading Researchers

December 12th 2008

An overview of the Susan G. Komen for the Cure awards held at this year's San Antonio Breast Cancer Symposium.

The Jury Is In

December 12th 2008

News from SABCS: Aromatase inhibitors are more effective than tamoxifen.

The Implications of Micrometastases in Early-Stage Breast Cancer Revealed

December 12th 2008

A brief look at how micrometasteses of the breast are being treated and the results from the MIRROR study which looked at whether or not micrometastases are predictive of recurrence.

Fresh Insights Into Hormonal Therapies

December 12th 2008

CURE Editor-in-Chief Debu Tripathy, MD, blogs on medical issues from SABCS.

Low-Dose Estradiol as Effective as High Dose in Treating Aromatase Inhibitor-Resistant Breast Cancer

December 12th 2008

A brief summary of the role estrogen plays in helping treat breast cancer patients who are initially resistant to aromatase inhibitors.

Examining Treatment Options and Side Effects

December 12th 2008

Advocate Joan Venticinque blogs about patient advocacy.

SABCS 2008 Marks the First Year of Collaboration

December 11th 2008

The American Association of Cancer Research has joined the Cancer Therapy Research Center at the University of Texas Health Science Center at San Antonio, and the Baylor College of Medicine in putting on this year's San Antonio Breast Cancer Symposium.

Advocates Converge at Breast Cancer Conference

December 11th 2008

Patient advocates lend a strong voice to this year’s San Antonio Breast Cancer Symposium.

SAN ANTONIO BREAST CANCER SYMPOSIUM 2007

December 11th 2008

A synopsis of last year's San Antonio Breast Cancer Symposium updates.

Advocates Put Triple Negative Breast Cancer to the Test

December 11th 2008

A look at the Triple Negative Breast Cancer Foundation’s roots and how the organization plans to expand their presence by funding necessary research and demanding that triple-negative breast cancer does not go unnoticed.

Advocates Face Many Choices in Era of Personalized Medicine

December 10th 2008

Advocate Joan Venticinque blogs about patient advocacy.

Finding Inspiration at San Antonio Breast Cancer Symposium

December 10th 2008

CURE publisher Susan McClure blogs from a survivor's perspective.

New Approaches Explored at San Antonio Breast Cancer Symposium

December 10th 2008

CURE Editor-in-Chief Debu Tripathy, MD, blogs on medical issues from SABCS.

New Ways of Studying Drugs are Needed to Succeed in Developing New Agents

December 10th 2008

Overview of education sessions during opening of SABCS.

Coping with Grief and Relief

November 1st 2008

Help for caregivers after patient death—emotional support, depression, grief, normal feelings, family support, and time to recover.

Setting Up a Caregiver Team

October 24th 2008

A guide and resources for how caregivers can set up a support team to organize help from family and friends, delegate responsibilities, ask for and accept support and favors during their caregiving role through the cancer journey.

Creating a Caregiver Notebook

October 24th 2008

Take it from a chronically disorganized caregiver: You want your cancer information organized and accessible.

Lung Cancer Patients Living Longer With Targeted Drugs

October 24th 2008

Avastin is one of a new class of drugs that works by targeting the newly formed blood vessels that develop around tumors, a process called antiangiogenesis—recent studies have seen positive survival results in colon cancer and now lung cancer.

The Pitfalls and Promises of Diagnosing Ovarian Cancer Early

October 24th 2008

Ovarian cancer, also known as “the silent killer,” may soon be detected earlier, giving women improved survival rates, with the recognition of specific early warning signs which including abdominal pain, abdominal bloating, urinary urgency or frequency, pelvic and lower back pressure, loss of appetite or feeling full quickly and abnormal vaginal bleeding.

CURExtra - Monitoring for Bladder Cancer Recurrence

October 23rd 2008

Bladder cancer has one of the highest recurrence rates, but there are many tests and ways to monitor for early detection including, urine cytology, cystoscopy, BladderChek, UroVysion, FISH and ImmunoCyt Bladder Cancer Monitoring Test.